Ustekinumab (Stelara)
From the هضم DIGEST medical team · GI, liver and endoscopy · Riyadh

Overview
Ustekinumab is a biologic that targets interleukins IL-12 and IL-23 — key cytokines in the inflammatory cascade of Crohn's disease and ulcerative colitis. It is given as a single intravenous dose for induction, then as subcutaneous injections for maintenance every 8 or 12 weeks.
Key Uses
Moderate-to-severe Crohn's disease (including after anti-TNF failure)
Moderate-to-severe ulcerative colitis
Also approved for plaque psoriasis and psoriatic arthritis
How It Works
Binds the p40 subunit shared by IL-12 and IL-23, blocking their pro-inflammatory signalling
Reduces Th1 and Th17 immune cell activity — key drivers of IBD inflammation
Induction: single weight-based IV infusion; maintenance: 90 mg SC every 8 or 12 weeks
Favourable safety profile — one of the lowest infection rates among IBD biologics
Safety & Self-Care
TB and hepatitis B screening before starting
Generally well tolerated — injection site reactions and mild upper respiratory infections are most common side effects
Avoid live vaccines; keep inactivated vaccines current
Self-injection can be learned at the clinic — training is provided
Store pre-filled syringes in the refrigerator; allow to reach room temperature before injecting
Contact Your IMCC Team
Contact your IMCC team if symptoms flare between doses, you develop infection signs, or if you are planning pregnancy or any surgical procedure.
What ustekinumab is and how it is given
Ustekinumab is a biologic that blocks interleukins 12 and 23, two proteins involved in the immune inflammation seen in Crohn's disease and ulcerative colitis. It is also used for psoriasis and psoriatic arthritis. For bowel disease it is usually started with a single intravenous infusion, followed by injections under the skin that are repeated every eight to twelve weeks, so the injections are infrequent. Biosimilar versions are now available. It is prescribed by a specialist, who decides the schedule.
Side effects, safety and monitoring
Ustekinumab is usually well tolerated. Common effects are colds and upper respiratory infections, headache, tiredness and injection-site redness. As with other immune-targeting drugs, infections are the main concern, and you are screened for tuberculosis and hepatitis B first. Rare effects include serious infections and allergic reactions. Skin changes should be checked during treatment, and live vaccines should be avoided. Your specialist will review your symptoms, blood tests and stool inflammation markers to check that it is working.
Frequently Asked Questions
What is ustekinumab used for?
How often is ustekinumab injected?
What are the side effects of ustekinumab?
Can ustekinumab be stopped if I am in remission?
Share this with someone who needs it:
Have questions or need a consultation?
Our GI specialists are ready to help you
Same-week appointments · WhatsApp replies during working hours